Syngene International Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹911Cr
- +2.2% YoY
- +4.2% QoQ
- Net profit
- ₹67Cr
- −36.8% YoY
- −23% QoQ
- Margin
- 22%
- −5 pp YoY
- −2 pp QoQ
Top 10 Healthcare Services companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5). FY 2026 is viewed as a transient year with a mid-single-digit revenue growth guidance and mid-20s EBITDA margin expected; PAT margins are declining but this is considered transient and driven by one-offs.
From Syngene International Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5).
- Research services have shown sustained growth momentum, supported by increased biotech venture capital funding, expected to accelerate growth (Page 6).
- The global Phase III clinical trial awarded to Syngene is a strategic growth opportunity, with revenue expected to grow over FY '27 and '28 as the trial progresses (Pages 5, 14, 16).
- Current growth is moderated by inventory correction in biologics manufacturing but underlying business remains robust, with a view that FY '27 and '28 could be strong growth years (Pages 7, 12, 13).
2 more points from Syngene International Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Syngene International Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Syngene invested roughly $200 million over the last 2 years in building capacity and capability, including biologics capacities.
- For FY '26, guided capex investment is $45 million, with an additional $10 million for the Bayview facility.
- Investment focus includes new modalities such as peptides, ADCs, biologics, and commercialization scale-up.
- New peptide facility being built in Mangalore to expand clinical and commercial scale capabilities.
- Bayview (Baltimore) biologics facility to commence commercialization in H2 FY '26; recruitment and ramp-up ongoing.
- Biologics manufacturing facility in Bangalore is operational and supplying GMP clinical supplies.
2 more points from Syngene International Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Syngene International Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Bayview facility in Baltimore is on track to commence commercialization in the second half of the fiscal year 2026, with initial batches and qualification batches planned.
- There are numerous ongoing discussions with potential clients for the Bayview facility, reflecting a positive outlook for its order book and ramp-up.
- The Unit 3 biologics facility in Bangalore, operational since May 2025, has started supplying GMP clinical batches to a U.S. biotech client and is beginning to see ramp-up in orders.
- Syngene has been awarded its first global Phase III clinical trial contract by a U.S.-based biotech, expected to generate revenue mainly in FY 2027 and 2028 as the trial progresses.
Syngene International Ltd — Quarterly revenue & net profit
Syngene International Ltd Q2 FY26 results — key figures
| ₹ Cr | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 911 | 891 | +2.2% | 874 | +4.2% |
| Operating profit (EBITDA) | 200 | 245 | -18.4% | 206 | -2.9% |
| Operating margin | 22% | 27% | -5 pp | 24% | -2 pp |
| Profit before tax | 85 | 137 | -38% | 101 | -15.8% |
| Net profit (PAT) | 67 | 106 | -36.8% | 87 | -23% |
| EPS (₹) | 1.67 | 2.64 | -36.7% | 2.15 | -22.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹833 Cr, net profit ₹32 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Syngene International's management said in earlier quarters
Others in Healthcare Services this season
- Maitreya Medicare (Q2 FY26)
23.92 crore (Page 26). Key investor presentation takeaways from Maitreya Medicare's Q2 FY26 investor presentation — and how it ranks against sector peers.
- Metropolis Healt (Q2 FY26)
Organic growth remains strong at around 12%, with no immediate price hikes planned. Key concall takeaways from Metropolis Healt's Q2 FY26 earnings call — and…
- 3B Blackbio (Q2 FY26)
Q2 FY 2025-26 sales: ₹3042.83 Lakh (including COVID sales ₹10.23 Lakh), up from ₹2457.55 Lakh in Q2 FY 2024-25. Key concall takeaways from 3B Blackbio DX Ltd's…
- Unihealth Hosp (Q2 FY26)
Nashik financial closure achieved via equity and bank debt (INR 22 crores from Bank of India). Key concall takeaways from Unihealth Hospitals Ltd's Q2 FY26…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Services
on management's own guidance
- Strong growth2
- Strong growth1
- IndegeneGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Syngene International Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Syngene International Ltd Q2 FY26 results?
Syngene expects medium to short-term growth driven by investments in new capabilities such as peptides, ADCs, and biologics facilities in Bangalore and Bayview (Page 5). FY 2026 is viewed as a transient year with a mid-single-digit revenue growth guidance and mid-20s EBITDA margin expected; PAT margins are declining but this is considered transient and driven by one-offs.
What is Syngene International Ltd share price analysis?
Syngene International Ltd currently shows a neutral. The stock trades at a P/E of 55.5 with a market cap of ₹16,427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Syngene International Ltd planning capital expenditure?
Syngene invested roughly $200 million over the last 2 years in building capacity and capability, including biologics capacities.
Keep Syngene International Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
